EMG
SCMP

Ellington Management Group’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Ellington Management Group’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-27,200
Closed -$286K – 976
2017
Q2 		$286K Buy
27,200
+14,800
+119% +$151K 0.04% 414
2017
Q1 		$136K Buy
+12,400
New +$144K ﹤0.01% 627
2015
Q2 		– Sell
-37,300
Closed -$580K – 1014
2015
Q1 		$580K Buy
+37,300
New +$578K 0.12% 239

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ellington Management Group's SCMP Position: Q3 2017 in Review

Ellington Management Group sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q3 2017, closing a stake of 27,200 shares — an estimated $286K sold.

Ellington Management Group first reported a position in SCMP in Q1 2015 and held it in 3 quarters. The position peaked at $580K in Q1 2015. 178 funds tracked by Wall St. Rank hold SCMP as of Q3 2017.

  • Ellington Management Group reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Ellington Management Group sold 27,200 Sucampo Pharmaceuticals, Inc. shares in Q3 2017, an estimated $286K.
  • Ellington Management Group first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 3 quarters.
  • Ellington Management Group's Sucampo Pharmaceuticals, Inc. position peaked at $580K in Q1 2015.
  • 178 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2017.

Based on Ellington Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.